glp-1 agonists mechanism of action Mechanisms of GLP-1RA GLP-1 & GIP Agonists |

Nonetheless, comprehensive real-world economic assessments across various healthcare systems are few, highlighting a significant research need for informed policy choices about coverage and accessibility

Further, many available clinical-based studies had incomplete or an absence of details of the medication or patient demographics including medications, medical and/or surgical history, and other notable findings such as GI symptoms

India Patent expires: March 2026 Adult population: 947 million Proportion of adults living with obesity a : 8% Proportion of adults living with diabetes b : 11% China Patent expires: March 2026 Adult population: 1.07 billion Proportion of adults living with obesity a : 9% Proportion of adults living with diabetes b : 12% Brazil Patent expires: March 2026 Adult population: 155 million Proportion of adults living with obesity a : 31% Proportion of adults living with diabetes b : 11% Trkiye Patent expires: 2026 Adult population: 59.0 million Proportion of adults living with obesity a : 36% Proportion of adults living with diabetes b : 16% Canada Patent expires: 2026 Adult population: 29.1 million Proportion of adults living with obesity a : 27% Proportion of adults living with diabetes b : 10% World Population: 8.23 billion More than 1 billion people in the world have a body mass index (BMI) 30 kg/m 2

doi: 10.1161/STROKEAHA.125.053075 Moaket, O.S

PYY plays a key role in the resolution of diabetes following bariatric surgery in humans

The drugs, which also include Mounjaro and Zepbound (tirzepatide), as well as Victoza and Trulicity, all belong to a class of medications known as glucagon-like peptide 1 (GLP-1) receptor agonists